MiNK Therapeutics, Inc. (NASDAQ:INKT) Q1 2024 Earnings Conference Call May 14, 2024 8:30 AM ET

Company Participants

Zack Armen - Head, Investor Relations
Jennifer Buell - President and Chief Executive Officer
Marc Van Dijk - Chief Scientific Officer
Christine Klaskin - Principal Financial and Accounting Officer
Dr. Dhan Chand - Head of Discovery at Agenus

Conference Call Participants

Emily Bodnar - H.C. Wainwright
Jack Allen – Baird
Matthew Phipps - William Blair

Operator

Good morning, and welcome to the MiNK Therapeutics' First Quarter 2024 Conference Call and Webcast. [Operator Instructions]. Please note this event is being recorded. If anyone has any objections you may disconnect at this time.

I would now like to turn the conference over to Zack Armen, MiNK’s Investor Relations. Zack go ahead.

Zack Armen

Thank you, Operator, and thank you all for joining us today. Today's call is being webcast and will be available on our website for replay.

I'd like to remind you that this call will include forward-looking statements, including statements regarding our clinical development, regulatory and commercial plans, and timelines, as well as timelines for data release and partnership opportunities among other updates. These statements are subject to risks and uncertainties, and we refer you to our SEC filings available on our website for more details on these risks.

Joining me today are Dr. Jennifer Buell, President and Chief Executive Officer; Dr. Marc Van Dijk, Chief Scientific Officer and Christine Klaskin, Principal Financial and Accounting Officer.

Now, I'd like to turn the call over to Dr. Buell to highlight our progress for this quarter.

Jennifer Buell

Thank you very much, Zack. It's a privilege to connect with all of you this morning to discuss our achievements in the first quarter and the milestones that advance our long-term strategic goals.

Today, I will highlight our latest clinical advancements notably in our leading programs, AgenT-797 and MiNK-215. I will also discuss our strength and financial foundation and outline our plans for sustained innovation and growth.

Let's start by our progress in streamlining operations and our financials. This quarter, we focus on advancing our pipeline, improving our operational efficiency and fortifying our financial health. Since this time last year, we have successfully reduced our operating expenses by over 45% through improved manufacturing efficiency, strategic infrastructure alignment and most critically, the external nondilutive financing to support our ongoing Phase II trial in second line gastric cancer. This financial prudence has enabled us to allocate resources more effectively towards accelerating our key clinical programs.